Table 1.
Compounds used in this study, their mode of action, and medical use.
| Chemical structure | Target/MoA | Indication/Use | |
|---|---|---|---|
| Reference drugs | |||
| Benznidazole [31593] |
|
Oxydative stress after activation by nitroreductase I | Chagas disease |
| Fexinidazole [68792] |
|
Oxydative stress after activation by nitroreductase I | Human African trypanosomiasis |
| Lipid signaling | |||
| Bezafibrate [39042] |
|
Peroxisome proliferator-activated receptor α agonist | Hyperlipidemia |
| D609 [4234241] |
|
Phosphatidylcholine-specific phospholipase C | Experimental |
| FTY720 [107969] |
|
Parent molecule (Fingolimod) of FTY720-P |
Multiple sklerosis, immuno-modulatory |
| FTY720-P [9908268] |
|
Sphingosine-1-phosphate-receptors | see above |
| Sterol synthesis | |||
| Quinuclidine [7527] |
|
Derivatives inhibit squalene synthase (Erg9) |
Experimental |
| 3-Amino quinuclidine [123238] |
|
Derivatives inhibit squalene synthase (Erg9) |
Experimental |
| Ro48-8071 [1949] |
|
Oxidosqualene cyclase (Erg7) |
Experimental |
| Posaconazole [468595] |
|
Lanosterol 14-α demethylase (Erg11) |
Antifungal |
| Tomatidine [65576] |
|
Sterol 24-C-methyltransferase (Erg6) | Natural dietary supplement, experimental |
| TMP-153 [125289] |
|
Sterol O-acyltransferase (ACAT) |
Experimental |
| Sphingolipid metabolism | |||
| Myriocin [6438394] |
|
Serine palmitoyltransferase | Fungal toxin, experimental |
| Fumonisin B1 [2733487] |
|
Ceramide synthase | Fungal toxin, experimental |
| PDMP [3129] |
|
Glucosylceramide synthase | Experimental |
| AMP-Deoxynojirimycin [9822159] |
|
Non-lysosomal glucosylceramidase | Experimental |
| Amitriptyline [2160] |
|
Acid sphingomyelinase | Depression |
| GW4869 [16078967] |
|
Neutral sphingomyelinase | Experimental |
Numbers in brackets are PubChem compound ID numbers (pubchem.ncbi.nlm.nih.gov; Kim et al., 2021).